close

Fenwick Represents ResMed in Joint Venture with Verily

August 03, 2018

​​Fenwick & West represented ResMed (NYSE: RMD, ASX:RMD), a global leader in sleep apnea treatment and connected health solutions, in its agreement to form a new joint venture with Verily Life Sciences, an Alphabet company developing tools to collect and organize health data. The joint venture, subject to customary closing conditions, including regulatory approvals, will operate as a separate venture from ResMed and Verily.

Combining ResMed’s expertise in sleep apnea and Verily’s advanced health data analytics technologies, the U.S.-based joint venture will study the health and financial impacts of undiagnosed and untreated sleep apnea. The two companies will collaborate to develop software solutions that enable healthcare providers to more efficiently identify, diagnose and treat the millions suffering from sleep related disorders. More information regarding ResMed’s joint venture with Verily can be obtained from the company announcement.

The Fenwick transaction team was led by Stefano Quintini and Dawn Belt and also included technology transactions lawyers Mangesh Kulkarni and Terry Gao; corporate lawyer Alina Azizian; and tax lawyer Will Skinner.